title: Xamoterol monotherapy in heart failure. The European 'Corwin' Group.
abstract: The effect of xamoterol as sole therapy was investigated in randomized, double-blind, placebo-controlled studies involving 425 patients with mild to moderate heart failure. When compared with placebo, xamoterol produced improvements in exercise capacity, clinical signs, symptoms and quality of life with a low incidence of adverse experiences. Xamoterol is effective as monotherapy in heart failure.
authors.affiliation: ICI Pharmaceuticals, Macclesfield, Cheshire, U.K.
authors.forename: R M
authors.initials: RM
authors.lastname: Timewell
authors.forename: R D
authors.initials: RD
authors.lastname: Stark
authors.forename: H F
authors.initials: HF
authors.lastname: Marlow
mesh_terms: D000318:Adrenergic beta-Agonists / Q000009:adverse effects / Q000627:therapeutic use*; D000368:Aged; D002303:Cardiac Output, Low / Q000188:drug therapy*; D004311:Double-Blind Method; D004341:Drug Evaluation; D006801:Humans; D011412:Propanolamines / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D017307:Xamoterol
chemical_list: D000318:Adrenergic beta-Agonists; D011412:Propanolamines; D017307:Xamoterol